Literature DB >> 17587223

Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1).

Richard T Moxley1, Eric L Logigian, William B Martens, Chris L Annis, Shree Pandya, Richard T Moxley1, Cheryl A Barbieri, Nuran Dilek, Allen W Wiegner, Charles A Thornton.   

Abstract

The aim of this study was to develop a reliable, sensitive, quantitative measure of grip myotonia and strength and to determine whether CTG repeat length is correlated with grip myotonia and with muscle strength in myotonic dystrophy type 1 (DM1). Three maximum voluntary isometric contractions (MVICs) of the finger flexors (i.e., handgrip) were recorded on 2 successive days using a computerized handgrip myometer in 29 genetically confirmed DM1 patients and 17 normals. An automated computer program calculated MVIC peak force (PF) and relaxation times (RTs) along the declining (relaxation) phase of the force recordings at 90%, 75%, 50%, 10%, and 5% of PF. Patients also underwent quantitative strength testing (QST) manual muscle testing (MMT). The patients had longer grip RTs and lower PFs than normals. RT (90% to 5%) was above the normal mean +2.5 SD in 25 (86%) patients. In DM1, prolongation of RT was mainly in the terminal (50% to 5%), rather than the initial (90% to 50%) phase of relaxation. PFs and RTs for each patient were reproducible on consecutive days. RTs were positively correlated with leukocyte CTG repeat length, whereas measures of muscle strength, such as PF, QST, and MMT, were negatively correlated with repeat length. We conclude that computerized handgrip myometry provides a sensitive, reliable measure of myotonia and strength in DM1 and offers a method to assess natural history and response to treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17587223     DOI: 10.1002/mus.20822

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  18 in total

1.  Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes.

Authors:  Gayle Overend; Cécilia Légaré; Jean Mathieu; Luigi Bouchard; Cynthia Gagnon; Darren G Monckton
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

2.  Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Authors:  Chad Heatwole; Rita Bode; Nicholas E Johnson; Jeanne Dekdebrun; Nuran Dilek; Katy Eichinger; James E Hilbert; Eric Logigian; Elizabeth Luebbe; William Martens; Michael P Mcdermott; Shree Pandya; Araya Puwanant; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

3.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Authors:  E L Logigian; W B Martens; R T Moxley; M P McDermott; N Dilek; A W Wiegner; A T Pearson; C A Barbieri; C L Annis; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

4.  Endocrine function in 97 patients with myotonic dystrophy type 1.

Authors:  M C Ørngreen; P Arlien-Søborg; M Duno; J M Hertz; J Vissing
Journal:  J Neurol       Date:  2012-02-17       Impact factor: 4.849

5.  Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.

Authors:  Chad R Heatwole; Katy J Eichinger; Deborah I Friedman; James E Hilbert; Carlayne E Jackson; Eric L Logigian; William B Martens; Michael P McDermott; Shree K Pandya; Christine Quinn; Alexis M Smirnow; Charles A Thornton; Richard T Moxley
Journal:  Arch Neurol       Date:  2010-09-13

6.  The Change of Grip Strength in a Patient with Congenital Myotonic Dystrophy Over a 4-year Period.

Authors:  Shin Kikuchi; Naoki Kozuka; Eiji Uchida; Takafumi Ninomiya; Haruyuki Tatsumi; Hidekatsu Takeda; Nobutada Tachi
Journal:  J Jpn Phys Ther Assoc       Date:  2008

7.  Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1.

Authors:  Eric L Logigian; Paul Twydell; Nuran Dilek; William B Martens; Chris Quinn; Allen W Wiegner; Chad R Heatwole; Charles A Thornton; Richard T Moxley
Journal:  Muscle Nerve       Date:  2010-02       Impact factor: 3.217

8.  A quantitative measure of handgrip myotonia in non-dystrophic myotonia.

Authors:  Jeffrey M Statland; Brian N Bundy; Yunxia Wang; Jaya R Trivedi; Dipa Raja Rayan; Laura Herbelin; Merideth Donlan; Rhonda McLin; Katy J Eichinger; Karen Findlater; Liz Dewar; Shree Pandya; William B Martens; Shannon L Venance; Emma Matthews; Anthony A Amato; Michael G Hanna; Robert C Griggs; Richard J Barohn
Journal:  Muscle Nerve       Date:  2012-10       Impact factor: 3.217

9.  Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Chad Heatwole; Elizabeth Luebbe; Spencer Rosero; Katy Eichinger; William Martens; James Hilbert; Jeanne Dekdebrun; Nuran Dilek; Christine Zizzi; Nicholas Johnson; Araya Puwanant; Rabi Tawil; Giovanni Schifitto; Christopher A Beck; J Franklin Richeson; Wojciech Zareba; Charles Thornton; Michael P McDermott; Richard Moxley
Journal:  Neurology       Date:  2020-10-12       Impact factor: 9.910

10.  Splicing biomarkers of disease severity in myotonic dystrophy.

Authors:  Masayuki Nakamori; Krzysztof Sobczak; Araya Puwanant; Steve Welle; Katy Eichinger; Shree Pandya; Jeannne Dekdebrun; Chad R Heatwole; Michael P McDermott; Tian Chen; Melissa Cline; Rabi Tawil; Robert J Osborne; Thurman M Wheeler; Maurice S Swanson; Richard T Moxley; Charles A Thornton
Journal:  Ann Neurol       Date:  2013-12       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.